Kiniksa Pharmaceuticals Files 8-K
Ticker: KNSA · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1730430
| Field | Detail |
|---|---|
| Company | Kiniksa Pharmaceuticals International, PLC (KNSA) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, SEC-filing
TL;DR
Kiniksa filed an 8-K on 6/5/25 for standard reporting - no major news.
AI Summary
Kiniksa Pharmaceuticals International, plc filed an 8-K on June 5, 2025, reporting information under Regulation FD and including financial statements and exhibits. The company, incorporated in England and Wales, has its principal executive offices in London. This filing does not appear to contain specific financial transaction details or material events beyond standard reporting requirements.
Why It Matters
This filing indicates standard corporate reporting activity for Kiniksa Pharmaceuticals, providing updates on financial statements and exhibits as required by the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any new risks or material events.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Registrant
- June 5, 2025 (date) — Date of earliest event reported
- England and Wales (jurisdiction) — State or other jurisdiction of incorporation or organization
- London (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 5, 2025.
Where are Kiniksa Pharmaceuticals International, plc's principal executive offices located?
Kiniksa Pharmaceuticals International, plc's principal executive offices are located at 23 Old Bond Street, Floor 3, London, W1S 4PZ, England, United Kingdom.
What is the company's state of incorporation?
The company's state of incorporation is England and Wales.
What is the Registrant's telephone number?
The Registrant's telephone number is (781) 431-9100.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Kiniksa Pharmaceuticals International, plc (KNSA).